Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Validated animal models for antiseizure drug (ASD) discovery: Advantages and potential pitfalls in ASD screening.

Barker-Haliski M, Steve White H.

Neuropharmacology. 2019 Aug 27:107750. doi: 10.1016/j.neuropharm.2019.107750. [Epub ahead of print] Review.

PMID:
31469995
2.

Repeated Intraperitoneal Administration of Low-Concentration Methylcellulose Leads to Systemic Histologic Lesions Without Loss of Preclinical Phenotype.

Meeker S, Beckman M, Knox KM, Treuting PM, Barker-Haliski M.

J Pharmacol Exp Ther. 2019 Oct;371(1):25-35. doi: 10.1124/jpet.119.257261. Epub 2019 Aug 2.

PMID:
31375638
3.

How do we choose the appropriate animal model for antiseizure therapy development?

Barker-Haliski M.

Expert Opin Drug Discov. 2019 Oct;14(10):947-951. doi: 10.1080/17460441.2019.1636782. Epub 2019 Jun 28.

PMID:
31248287
4.

Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models.

Patra PH, Barker-Haliski M, White HS, Whalley BJ, Glyn S, Sandhu H, Jones N, Bazelot M, Williams CM, McNeish AJ.

Epilepsia. 2019 Feb;60(2):303-314. doi: 10.1111/epi.14629. Epub 2018 Dec 26.

5.

Intravenously Administered Ganaxolone Blocks Diazepam-Resistant Lithium-Pilocarpine-Induced Status Epilepticus in Rats: Comparison with Allopregnanolone.

Saporito MS, Gruner JA, DiCamillo A, Hinchliffe R, Barker-Haliski M, White HS.

J Pharmacol Exp Ther. 2019 Mar;368(3):326-337. doi: 10.1124/jpet.118.252155. Epub 2018 Dec 14.

PMID:
30552296
6.

A companion to the preclinical common data elements for pharmacologic studies in animal models of seizures and epilepsy. A Report of the TASK3 Pharmacology Working Group of the ILAE/AES Joint Translational Task Force.

Barker-Haliski M, Harte-Hargrove LC, Ravizza T, Smolders I, Xiao B, Brandt C, Löscher W.

Epilepsia Open. 2018 Sep 15;3(Suppl Suppl 1):53-68. doi: 10.1002/epi4.12254. eCollection 2018 Nov.

7.

Lamotrigine-resistant corneal-kindled mice: A model of pharmacoresistant partial epilepsy for moderate-throughput drug discovery.

Koneval Z, Knox KM, White HS, Barker-Haliski M.

Epilepsia. 2018 Jun;59(6):1245-1256. doi: 10.1111/epi.14190. Epub 2018 May 11.

8.

Neuroinflammation in epileptogenesis: Insights and translational perspectives from new models of epilepsy.

Barker-Haliski ML, Löscher W, White HS, Galanopoulou AS.

Epilepsia. 2017 Jul;58 Suppl 3:39-47. doi: 10.1111/epi.13785.

9.

Validation of a Preclinical Drug Screening Platform for Pharmacoresistant Epilepsy.

Barker-Haliski ML, Johnson K, Billingsley P, Huff J, Handy LJ, Khaleel R, Lu Z, Mau MJ, Pruess TH, Rueda C, Saunders G, Underwood TK, Vanegas F, Smith MD, West PJ, Wilcox KS.

Neurochem Res. 2017 Jul;42(7):1904-1918. doi: 10.1007/s11064-017-2227-7. Epub 2017 Mar 16.

PMID:
28303498
10.

Acute treatment with minocycline, but not valproic acid, improves long-term behavioral outcomes in the Theiler's virus model of temporal lobe epilepsy.

Barker-Haliski ML, Heck TD, Dahle EJ, Vanegas F, Pruess TH, Wilcox KS, White HS.

Epilepsia. 2016 Dec;57(12):1958-1967. doi: 10.1111/epi.13577. Epub 2016 Oct 14.

11.

Acute cognitive impact of antiseizure drugs in naive rodents and corneal-kindled mice.

Barker-Haliski ML, Vanegas F, Mau MJ, Underwood TK, White HS.

Epilepsia. 2016 Sep;57(9):1386-97. doi: 10.1111/epi.13476. Epub 2016 Jul 28.

12.

Neuronal Injury, Gliosis, and Glial Proliferation in Two Models of Temporal Lobe Epilepsy.

Loewen JL, Barker-Haliski ML, Dahle EJ, White HS, Wilcox KS.

J Neuropathol Exp Neurol. 2016 Apr;75(4):366-78. doi: 10.1093/jnen/nlw008. Epub 2016 Mar 4.

13.

Glutamatergic Mechanisms Associated with Seizures and Epilepsy.

Barker-Haliski M, White HS.

Cold Spring Harb Perspect Med. 2015 Jun 22;5(8):a022863. doi: 10.1101/cshperspect.a022863. Review.

14.

Disease modification in epilepsy: from animal models to clinical applications.

Barker-Haliski ML, Friedman D, French JA, White HS.

Drugs. 2015 May;75(7):749-67. doi: 10.1007/s40265-015-0395-9. Review.

PMID:
25925798
15.
16.

How clinical development can, and should, inform translational science.

Barker-Haliski M, Friedman D, White HS, French JA.

Neuron. 2014 Nov 5;84(3):582-93. doi: 10.1016/j.neuron.2014.10.029. Epub 2014 Nov 5. Review.

17.

What are the arguments for and against rational therapy for epilepsy?

Barker-Haliski M, Sills GJ, White HS.

Adv Exp Med Biol. 2014;813:295-308. doi: 10.1007/978-94-017-8914-1_24. Review.

PMID:
25012386
18.

The GABA synapse as a target for antiepileptic drugs: a historical overview focused on GABA transporters.

Schousboe A, Madsen KK, Barker-Haliski ML, White HS.

Neurochem Res. 2014 Oct;39(10):1980-7. doi: 10.1007/s11064-014-1263-9. Epub 2014 Mar 14. Review.

PMID:
24627365
19.

Phasic-like stimulation of the medial forebrain bundle augments striatal gene expression despite methamphetamine-induced partial dopamine denervation.

Howard CD, Pastuzyn ED, Barker-Haliski ML, Garris PA, Keefe KA.

J Neurochem. 2013 May;125(4):555-65. doi: 10.1111/jnc.12234. Epub 2013 Apr 1.

20.

Expression of the core exon-junction complex factor eukaryotic initiation factor 4A3 is increased during spatial exploration and striatally-mediated learning.

Barker-Haliski ML, Pastuzyn ED, Keefe KA.

Neuroscience. 2012 Dec 13;226:51-61. doi: 10.1016/j.neuroscience.2012.09.003. Epub 2012 Sep 12.

21.

Disruption of subcellular Arc/Arg 3.1 mRNA expression in striatal efferent neurons following partial monoamine loss induced by methamphetamine.

Barker-Haliski ML, Oldenburger K, Keefe KA.

J Neurochem. 2012 Dec;123(5):845-55. doi: 10.1111/jnc.12017. Epub 2012 Oct 10.

Supplemental Content

Loading ...
Support Center